Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen
Aim. To implement in 2009—2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2015-10-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/view/31822 |
| _version_ | 1818308477406150656 |
|---|---|
| author | N V Efremova L L Bolotskaya D S Atarshchikov O N Bondarenko A V Ilyin M V Shestakova |
| author_facet | N V Efremova L L Bolotskaya D S Atarshchikov O N Bondarenko A V Ilyin M V Shestakova |
| author_sort | N V Efremova |
| collection | DOAJ |
| description | Aim. To implement in 2009—2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. Subjects and methods. The program covered 100 patients aged 19 to 25 years from 7 regions of the Russian Federation, who had had DM onset at the age of 9—13 years, were using human recombinant insulins as continuous insulin therapy, and had glycated hemoglobin (HbA1c) levels of 7 to 9%. The main inclusion criterion was switching to insulin therapy with the human insulin analogues Lantus and Apidra. Results. A total 41 men and 59 women were followed up. Their mean baseline HbA1c level was 8.3±0.7%. After 24 months of therapy, HbA1c was significantly decreased to 7.7±0.7%; its change compared with that at Visit 1 was –0.6±0.6% (p |
| first_indexed | 2024-12-13T07:14:54Z |
| format | Article |
| id | doaj.art-ef7d9c95ddd243039e3f28f5fe344458 |
| institution | Directory Open Access Journal |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| last_indexed | 2024-12-13T07:14:54Z |
| publishDate | 2015-10-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj.art-ef7d9c95ddd243039e3f28f5fe3444582022-12-21T23:55:35Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422015-10-018710424928838Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimenN V EfremovaL L BolotskayaD S AtarshchikovO N BondarenkoA V IlyinM V ShestakovaAim. To implement in 2009—2012 the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen in patients with type 1 diabetes mellitus (DM) to evaluate the efficiency and safety of therapy with human insulin analogues. Subjects and methods. The program covered 100 patients aged 19 to 25 years from 7 regions of the Russian Federation, who had had DM onset at the age of 9—13 years, were using human recombinant insulins as continuous insulin therapy, and had glycated hemoglobin (HbA1c) levels of 7 to 9%. The main inclusion criterion was switching to insulin therapy with the human insulin analogues Lantus and Apidra. Results. A total 41 men and 59 women were followed up. Their mean baseline HbA1c level was 8.3±0.7%. After 24 months of therapy, HbA1c was significantly decreased to 7.7±0.7%; its change compared with that at Visit 1 was –0.6±0.6% (phttps://ter-arkhiv.ru/0040-3660/article/view/31822type 1 diabetes mellitushuman insulin analoguesglargine (lantus)glulisine (apidra)glycemic controlhypoglycemia |
| spellingShingle | N V Efremova L L Bolotskaya D S Atarshchikov O N Bondarenko A V Ilyin M V Shestakova Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen Терапевтический архив type 1 diabetes mellitus human insulin analogues glargine (lantus) glulisine (apidra) glycemic control hypoglycemia |
| title | Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen |
| title_full | Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen |
| title_fullStr | Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen |
| title_full_unstemmed | Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen |
| title_short | Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen |
| title_sort | use of human insulin analogues in young patients with type 1 diabetes mellitus results of the result observational program on the use of insulin glargine lantus in combination with insulin glulisine apidra as a basal bolus regimen |
| topic | type 1 diabetes mellitus human insulin analogues glargine (lantus) glulisine (apidra) glycemic control hypoglycemia |
| url | https://ter-arkhiv.ru/0040-3660/article/view/31822 |
| work_keys_str_mv | AT nvefremova useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen AT llbolotskaya useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen AT dsatarshchikov useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen AT onbondarenko useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen AT avilyin useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen AT mvshestakova useofhumaninsulinanaloguesinyoungpatientswithtype1diabetesmellitusresultsoftheresultobservationalprogramontheuseofinsulinglarginelantusincombinationwithinsulinglulisineapidraasabasalbolusregimen |